BIIB · News · 20260807N
Acquisition / Partnership / Divestiture
BIOGEN INC. · 2026-08-07 · Importance 71 · Surprise 60 · In source text
Biogen completed its acquisition of RayThera, Inc. on August 6, 2026, expanding its immunology portfolio with multiple small-molecule assets. The transaction carries total consideration of up to $1 billion, comprising $225 million in upfront cash and $775 million contingent on future clinical and regulatory milestones. RayThera’s lead program entered Phase 1 development in July 2026, and Biogen will oversee development, manufacturing, and global commercialization of the acquired assets. The deal is Biogen’s third significant immunology transaction in 2026 and supports its strategy to diversify into oral immunology therapies.
Key facts
- The acquisition of RayThera is valued at up to $1 billion. source
- Biogen will now manage the development, manufacturing, and global commercialization of all acquired RayThera assets. source
- This acquisition is Biogen's third significant immunology transaction in 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Biogen will now manage the development, manufacturing, and global commercialization of all acquired RayThera assets. |